Using a natural compound to improve insulin sensitivity in type 2 diabetes
Official title: Targeting galectin-3 to overcome insulin resistance in type 2 diabetes
Funded at Glycomantra, INC. · NIH-10916440 · Data updated 2026-11-12
This study is looking at a new treatment for type 2 diabetes that targets a protein called galectin-3, using a natural compound called TFD100, to help improve insulin resistance and potentially offer a new option for managing the condition.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Glycomantra, INC. NIH-funded |
| Lab location | 1 site (Halethorpe, United States) |
| Project start | May 22, 2020 |
| Project end | August 31, 2025 |
| Funding year | 2024 |
| Award (this year) | $1,864,171 |
| NIH project number | 5R44DK125126-03 |
| Project ID | NIH-10916440 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are adults diagnosed with type 2 diabetes, particularly those experiencing insulin resistance.
✕Less likely to help
Patients who do not have type 2 diabetes or those whose diabetes is not related to insulin resistance may not benefit from this research.
What this research studies
This research focuses on addressing insulin resistance, a major issue in type 2 diabetes, by targeting a protein called galectin-3. The team has developed a potent antagonist of galectin-3, known as TFD100, which is derived from a natural dietary source. The goal is to complete preclinical studies that will support an application to the FDA for a first-in-human clinical trial. If successful, this could lead to a new treatment option that directly affects insulin receptor signaling.
Why it matters
Potential benefit: If successful, this research could provide a novel treatment for patients with type 2 diabetes, potentially improving their insulin sensitivity and glucose control.
How similar studies have gone: While targeting galectin-3 is a novel approach, similar strategies in addressing insulin resistance have shown promise in preliminary studies.
Where this research is happening
-
Glycomantra, INC.
Halethorpe, United States Active
Researchers
- Principal investigator: Ahmed, Hafiz — Glycomantra, INC.
- Study coordinator: Ahmed, Hafiz
Related research
Other NIH-funded projects on the same topics.
-
How pancreatic alpha cells respond in insulin resistance and type 2 diabetes
This project looks at why pancreatic alpha cells release too much glucagon in adults with insulin resistance or type 2 diabetes.
-
Improving blood flow and insulin response in type 2 diabetes
This study is looking at how a protein called ADAM17 affects blood flow and insulin response in people with type 2 diabetes, to see if blocking this protein can help improve blood sugar control and lower heart risks.
-
Investigating how muscle cells behave in insulin resistance and type 2 diabetes
This study is looking at how changes in muscle cells can make it harder for people with type 2 diabetes to use insulin properly, and it hopes to find new ways to help improve insulin sensitivity for better blood sugar control.
-
Understanding how pancreatic alpha cells respond to insulin resistance and type 2 diabetes
This study is looking at how certain cells in the pancreas behave when someone has type 2 diabetes, especially when the body struggles to use insulin properly, and it aims to find new ways to help manage diabetes better.
-
Subtyping Core for Research on the Causes of Type 2 Diabetes (SCORE-T2D)
A new U01 grant from a university research team aims to understand why Type 2 diabetes differs so much between people and how to tailor prevention and treatment.
-
Michigan Diabetes Project: A Peer-Led Self-Management Program for Adults with Type 2 Diabetes
A peer-led self-management program for adults with type 2 diabetes is being tested to see if it improves blood sugar control and daily diabetes care.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.